PYRAZOLO(3,4-D)AZEPINE, 3-(4-CHLOROPHENYL)-1,4,5,6,7,8-HEXAHYDRO-1-(PHENYLMETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT)

Bipolar Disorder

King's College LondonSmall moleculePhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

67 Active assets in the Bipolar Disorder cohort.

Asset / Sponsor	Phase	Rating
Asenapine Dr. Stavroula Rakitzi	Phase 4	BBB
LITHIUM, ELEMENTAL University of Aarhus	Phase 4	BBB
Seroquel® First Affiliated Hospital of Zhejiang University	Phase 4	BBB
CITALOPRAM University of Texas Southwestern Medical Center	Phase 4	BBB
Cipralex First Affiliated Hospital of Zhejiang University	Phase 4	BBB

View all 50 →

Same molecule, other indications

PYRAZOLO(3,4-D)AZEPINE, 3-(4-CHLOROPHENYL)-1,4,5,6,7,8-HEXAHYDRO-1-(PHENYLMETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT) is also rated in:

major depressive disorderDormant

CCC

Indicative ·

51 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →